Navigation Links
Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
Date:2/12/2009

NAPA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, announced today that positive study results from a clinical trial of Pyratine-XR(TM) in patients with rosacea will be presented February 13, 2009, at the 7th Annual South Beach Clinical Dermatology Symposium in Miami, Florida.

Dr. Mark Nestor, the Symposium chair, will be presenting "Cytokinins: Cutaneous Aging and Rosacea" at 4:45 PM.

Based on positive results demonstrated in previous studies of Pyratine-6(TM) (0.1% furfuryl tetrahydropyranyladenine) for the remediation of photodamaged skin and erythema, with resulting reduction in facial redness and fine wrinkles in as early as two weeks, Senetek initiated a clinical trial for assessing the effects of Pyratine-XR(TM) (0.125% furfuryl tetrahydropyranyladenine) in improving the clinical signs and symptoms of rosacea.

According to the National Rosacea Society, more than 14 million Americans have rosacea, yet only a small fraction are being treated. The chronic skin disease can affect adults and children of any skin type. While the cause is unknown and there is no cure, scientific advancements are now offering rosacea sufferers hope and a way to control the signs and symptoms of this potentially life-disruptive disorder.

Eighteen subjects with mild-to-moderate rosacea participated in a 48-week study at the University of California, Irvine, and were evaluated through physician assessments of inflammatory lesion count (papules and pustules), severity of erythema (redness) and telangiectasia (spider veins) and overall clinical improvement, as well as through patient assessments of signs and symptoms of rosacea and skin tolerance.

Data suggests that Pyratine-XR(TM) may offer important advantages over currently available treatments for rosacea, primarily oral and topical antibiotics, which involve long-term tolerability and other health concerns. Pyratine-XR(TM) produced a progressive decrease in the symptoms associated with rosacea including redness and lesions. All subject self-assessments showed good tolerability and cosmetic acceptability.

After 48 weeks, there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. The investigators saw continual, statistically significant mean improvement with Pyratine-XR(TM) treatment, including a 90% improvement in lesions, 45% improvement in erythema and a 28% improvement in telangiectasia. The product was well tolerated, and in an earlier assessment of 24 patients, there was a 41% mean improvement in skin dryness as early as week four, with results continuing to improve over the 48- week period. Pyratine-XR(TM) produced a significant improvement in skin barrier function at weeks 4 through 48 as measured by a decrease in water loss from the skin.

"We are incredibly pleased with the results reported in this rosacea- specific study, with continual improvement in lesions, redness and spider veins. Unlike current therapies, Pyratine-XR(TM) was well tolerated by all patients, and offers hope to a myriad of individuals suffering from facial redness, acne lesions and spider veins, such as those afflicted with eczema, atopic dermatitis and rosacea. We are pleased that the study results are being presented by Dr. Nestor at this prestigious meeting," said Frank J. Massino, Chairman and CEO of Senetek PLC. "The clinical trials are extremely promising, and we anticipate a tremendous physician and patient response to Pyratine- XR(TM), which will officially launch at the American Academy of Dermatology's 67th Annual Meeting in San Francisco, March 6-10, 2009."

About Senetek, PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

About Dr. Mark S. Nestor

Mark S. Nestor, M.D., Ph.D. is a board-certified dermatologist and dermatologic surgeon, and director of the Center for Cosmetic Enhancement in Aventura, Florida. Dr. Mark Nestor currently serves as President of the American Society for Photodynamic Therapy, and as a Volunteer Associate Professor of the University of Miami, Miller School of Medicine. He is the immediate Past President of the International Society of Cosmetic and Laser Surgeons.


'/>"/>
SOURCE Senetek, PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
2. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
5. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
6. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
7. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
8. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
9. Micromet Expands Committed Equity Financing Facility to $75 Million
10. German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... , May 4, 2016 ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved ... are expected to be developed in coming years. Many ... techniques. Cancer stem cell therapies are also expected to ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, ... contracted rheumatic fever, which damaged his heart. He continued ... But by June 2013, Shepherd,s heart was giving out ... death. On June 20, 2013, the Mesa, ... Artificial Heart (TAH-t). Like a heart transplant, the SynCardia ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 2016 , ... Fertility Centers of New England announced today the opening of ... Center provides convenient access to care for patients seeking fertility treatment in Maine. “We ... Comprehensive Care in Portland,” said Fertility Centers of New England President and CEO, Joseph ...
(Date:5/4/2016)... ... 2016 , ... Vasont Systems, a top component content management ... the latest release of Adobe FrameMaker, Release 2015. The integration of the Vasont® ... editing and storing XML. , The VUI creates a smooth continued ...
(Date:5/3/2016)... Minnesota (PRWEB) , ... May 04, 2016 , ... ... more than 40 national and global construction firms representing the Construction Industry Safety ... have joined forces with one purpose: to inspire everyone in the industry to ...
(Date:5/3/2016)... Garden City, NY (PRWEB) , ... May 04, 2016 , ... ... as a 2016-2017 inductee into its VIP Woman of the Year Circle. She ... leading networking organization exclusively for professional women, boasting more than 850,000 members and over ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... on Denver Business Journal, patients report dissatisfaction with numerous issues related to medical ... personnel, issues with billing, and poor bedside manner from hospital staff. Commenting on ...
Breaking Medicine News(10 mins):